Northwestern University Lead Academic Participating Site

项目概要/摘要 罗伯特·H。西北大学卢里综合癌症中心（LCC）有一个长期的 自1973年以来，NCTN参与ECOG成员的历史。目前，LCC 基础设施支持通过ECOG参与临床试验和辅助研究- ACRIN、SWOG、Alliance、NRG和COG。确认应计、参与和高级别 为了提高数据质量，LCC已被NCTN领导层选中参加高级 在2015年、2016年和2017年实施了“执行站点计划”（HPSI），以支持我们的基础设施， 使其能够继续参与NCTN试验。Lurie癌症中心对NCTN的总体应计费用 2014年3月1日至2017年8月31日期间的研究为400项，其中383项为干预性试验。 此外，LCC成员积极参与NCTN活动的领导。从3/1/14 和8/31/16，LCC成员担任网络组委员会和小组委员会 成员（74）、委员会和小组委员会主席和共同主席（19）、研究主席和共同主席 (22)，以及各种NCI指导委员会或工作组的成员（10）。此外该 大量网络集团出版物（65）和摘要（70）的作者或合著者 仅在过去3年中，调查人员就进一步证明了我们在 NCTN。 通过展示重大科学成就和新举措， 招聘有成就的高级教师和富有成效的初级教师，全面和 监督癌症相关临床试验的综合基础设施， 一个NCTN监督委员会，强调初级教师的指导，重大的财政 支持NCTN的活动和一个经验丰富和富有成效的领导， LCC在NCTN内持续活跃，证明了它的治理能力， 组织能力和承诺，以及高级管理人员的一般专业知识 领导团队来支持这个LAPS应用程序。

PROJECT SUMMARY/ABSTRACT The Robert H. Lurie Comprehensive Cancer Center of Northwestern University (LCC) has a long history of NCTN participation with ECOG membership since 1973. Currently, the LCC infrastructure supports participation in clinical trials and ancillary studies through the ECOG- ACRIN, SWOG, Alliance, NRG and COG. Recognized for accrual, participation, and high-level of data quality, the LCC has been selected by the NCTN leadership to participate in the High Performing Site Initiative (HPSI) in 2015, 2016 and 2017 to support our infrastructure and to enable continued participation in NCTN trials. The Lurie Cancer Center's overall accrual to NCTN studies during 3/1/14 - 8/31/17 was 400, 383 of which were accrued to Interventional trials. In addition, LCC members are heavily involved in the leadership of NCTN activities. From 3/1/14 and 8/31/16, LCC members have served as Network Group committee and subcommittee members (74), committee and subcommittee chairs and co-chairs (19), study chairs and co-chairs (22), and members of various NCI Steering Committees or Task Forces (10). In addition, the extensive number of Network Group publications (65) and abstracts (70) authored or co-authored by the investigators during the last 3 years alone further demonstrates our leadership role within the NCTN. Through demonstration of significant scientific accomplishments and new initiatives, recent recruitment of accomplished senior faculty and productive junior faculty, comprehensive and integrated infrastructure for oversight of cancer-related clinical trials including the establishment of a NCTN Oversight Committee, emphasis on mentoring of junior faculty, significant financial support of NCTN activities and a highly experienced and productive leadership which has been continuously active within the NCTN, the LCC has proved that it has the governance, organizational capabilities and commitment, as well as the general expertise of the senior leadership team to support this LAPS application.